Omeprazole or Aciphex?

When stratified for CYP2C19 biological group, 76% of extensive metabolizers, 84% of intermediate metabolizers, and 86% of poor metabolizers were cured of their H. pylori ill health (statistical comparisons not presented).
These observations led to the judgment that base hit therapy with omeprazole or aciphex, amoxicillin, and clarithromycin is a sufficiently effective tending for H. pylori contagion regardless of CYP2C19 condition.
Conflicting results have been shown with other PPIs.
One investigating chemical group demonstrated the effects of CYP2C19 genetic chemical phenomenon on clinical end points with omeprazole- and lansoprazole-based therapy. This mathematical group randomized 261 Altaic adults (86% men, mean age 49.0 ± 9.7 yrs) with endoscopically proved peptic ulcer disease (gastric or duodenal ulcers) who also were infected with H. pylori .
Three-bagger therapy was started with amoxicillin 1500 mg/day, clarithromycin 600 mg/day, and either omeprazole 40 mg/day or lansoprazole 60 mg/day for 1 week.
Eradication of H. pylori was judged on the base of development, histology, the rapid urease test, and the [13C]-urea air test.
Patients who failed this idiom were retreated with lansoprazole 120 mg/day and amoxicillin 2000 mg/day for 2 weeks.
Eradication rates for H. pylori were 73% (95% CI 64-82%), 92% (95% CI 86-97%), and 98% (95% CI 89-100%) in extensive metabolizers, intermediate metabolizers, and poor metabolizers, respectively.
This is a part of article Omeprazole or Aciphex? Taken from "Generic Aciphex (Rabeprazole) Review" Information Blog